News for Alterity Therapeutics Limited (ATH.AX)

”“ ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints ”“ ”“ MSA Atrophy Index (MSAai) enhances MSA diagnosis and

**media[617437]**

â\u0080\u0093 Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA â\u0080\u0093 MELBOURNE, Australia and SAN FRANCISCO, May

The ASX has been down 0.4% at around 8,205 points in morning…

Alterity Therapeutics (ASX:ATH), dual-listed on both the ASX and the NASDAQ, is the latest Aussie biotech to win an FDA tick with its drug...

Highlights Reported positive topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) led by robust cli

MELBOURNE, Australia and SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, ATHE) (”œAlterity” or ”œthe Company”), a bi

”“ Clinically Meaningful Efficacy Observed on Multiple Assessments ”“ ”“ Confirmed Target Engagement with Reduced Iron Signal in MSA Affected Brain Region

Alterity Therapeutics Limited (ATHE), Thursday announced the data from ATH434 Phase 2 trial in patients with Multiple System Atrophy or MSA. The findings showed clinically meaningful efficacy across multiple measures.

**media[584926]**

”“ Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders ”“ ”“ Capital raising was strongly supported by domestic and intern

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.18% to 44,795.97 while the NASDAQ fel...

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Thursday. The Dow traded up 0.26% to 44,829.59 while the NASDAQ gain...

**media[528039]**

Alterity Therapeutics (ASX: ATH) has announced positive topline results from a Phase 2 clinical trial of lead candidate ATH434-201 on patients with

**media[523364]**

Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025ATH434-201 trial in

**media[510655]**

”“ ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders ”“ ”“ Topline Data Expected in Early 2025 ”“